NMTC vs SABA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NMTC Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to NeuroOne Medical Technologies Corporation Common Stock (NMTC) driven by superior Growth & Margin, Options & Structure while SABA counters with relative strength in Momentum & Technical. Fundamentally, NMTC trades at N/M Forward P/E with -63.4% operating margin (+16.3% YoY revenue) versus SABA at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, NMTC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SABA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NMTC | SABA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.1M | $251.8M | Larger Scale | SABA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +16.3% | N/A | Higher Growth | NMTC |
| Operating Margin (TTM) Profitability | -63.4% | N/A | Higher Margin | NMTC |
| Net Profit Margin Profitability | -59.7% | N/A | Higher Margin | NMTC |
| Return on Equity (ROE) Capital Efficiency | -124.7% | N/A | Higher ROE | NMTC |
| 52-Week Range Position Momentum | 2% ($1โ$5) | 4% ($7โ$9) | Stronger Trend | SABA |
| Beta / 30D Volatility Risk Regime | 1.55ฮฒ ยท 105% Vol | 0.37ฮฒ ยท 13% Vol | Lower Realized Risk | SABA |
| Unified Institutional Score Composite Signal | 45.5 / 100 (HOLD) | 44.2 / 100 (HOLD) | Higher Composite | NMTC |